Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

Daiichi Sankyo has been ordered to pay an 8% royalty ... Insulet is celebrating a jury's verdict that rival South Korean firm EOFlow stole trade secrets relating to its wearable insulin pump ...

Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

North Korea warns of retaliation after US nuclear submarine docks in Busan Pyongyang warns of ‘acute military confrontation’ after USS Alexandria submarine docks in South Korean port.

Daiichi Sankyo had opposed the open offer made in 2018 after Northern TK Venture had acquired a 31% stake in Fortis. NTK had then filed a lawsuit against Daiichi Sankyo in November 2023.

Ukrainian President Volodymyr Zelenskiy said Russia could send up to 3,000 more North Korean troops to the front in its Kursk region, in comments at a press conference at the Munich Security ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Ukraine’s new enemies are learning on the battlefield but have fatal orders to follow to avoid capture, says Kyiv. Here are the key developments on the 1,055th day of Russia’s full-scale ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...